BRENNEN

Industries / Health / Health insurers and PBMs

Drug lists and pharmacy benefits

Deciding which medicines a plan pays for and what share the member pays, mostly through pharmacy benefit managers (PBMs), the companies that process drug claims, build the lists of covered drugs and bargain with drug makers and pharmacies.

7

Milestones achieved, from 1960s to 2024.

2

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 1960s

    Drug claims go to middlemen

    Pharmacy benefit managers began processing prescription claims and doing administrative work for health insurers in the late 1960s, by the account of the US Federal Trade Commission (FTC). Over time they took on the rest of the drug benefit: formularies, the lists of drugs a plan covers; rebates, the payments drug makers make in return for a good place on those lists; and the rates pharmacies are paid.

    ftc.gov

    Credit

    early US claims processors; the FTC's July 2024 interim staff report names no single company

  2. 1993

    A national buyer for medicines

    New Zealand created the Pharmaceutical Management Agency (Pharmac) in 1993, at first a company owned by the government's four health funding agencies, to get drug makers to offer lower prices. It paid the same rate for medicines that do the same job, a method called reference pricing, so the maker of a dearer drug had to cut its price or lose sales. From 1997 it ran tenders in which one supplier wins the funded market for an off-patent medicine, starting with paracetamol. Pharmac says more than half of funded medicines by volume are now tendered and that its annual tender saves about NZ$40 to 50 million a year.

    pharmac.govt.nz

    Credit

    Pharmac

  3. 2006

    Medicare drugs through private plans

    Medicare's optional drug benefit, Part D, created by a 2003 law, went into effect in 2006 and is run by private plans that set their own formularies. A study of the plans found that the share of drugs carrying a restriction, such as prior authorization (approval before the drug is covered), step therapy (try a cheaper drug first) or exclusion, rose from 31.9% in 2011 to 44.4% in 2020, and that by 2020 formularies excluded on average 44.7% of drugs sold only under a brand name. From 2025 the Inflation Reduction Act capped what an enrollee pays at $2,000 a year ($2,100 in 2026) and cut Medicare's share of the costliest claims from 80% to 20% for brand-name drugs, moving the rest to plans and drug makers; KFF counts 360 stand-alone drug plans for 2026, nearly half as many as in 2024.

    Lessonwhen plans were made to carry more of the costliest claims, many stand-alone plans left the market.

    cms.govdoi.orgkff.org

    Credit

    US Congress and the Centers for Medicare & Medicaid Services (CMS); study by Geoffrey Joyce of the University of Southern California and colleagues

  4. 2007

    Pharmacies dispense the contract drug

    German sickness funds have been allowed since 2003 to sign rebate contracts with drug makers. Since 2007 a pharmacist must hand out the version of an active ingredient on which the patient's fund holds a rebate contract, unless the doctor rules out substitution on the prescription. A patient who wants another brand pays the difference.

    bundesgesundheitsministerium.de

    Credit

    German Federal Ministry of Health and the Bundestag (law); the statutory sickness funds

  5. 2014

    Exclusion wins a discount

    Gilead priced its hepatitis C drug Sovaldi at $84,000 for a 12-week course. In December 2014 Express Scripts, then the largest PBM, made AbbVie's rival Viekira Pak its preferred drug for the commonest form of the virus and dropped Gilead's drugs. Gilead quickly struck its own deals with CVS Caremark and Anthem at discounts that industry sources put near 40% off list price, by the account of a US Senate Finance Committee investigation, which also found that many payers still limited treatment to patients with advanced liver scarring. Leaving drugs off the list became routine: the consultancy Xcenda counted 109 medicines on the three largest PBMs' standard exclusion lists in 2014 and 1,156 in 2022.

    Lessonthe threat of exclusion moved a price that a year without competitors had not..pdf).

    finance.senate.govmanagedhealthcareexecutive.com

    Credit

    Express Scripts and AbbVie; record by the staff of Senators Ron Wyden and Charles Grassley

  6. 2020

    States may regulate PBM pay

    Arkansas's Act 900 of 2015 effectively required PBMs to pay pharmacies at least what the pharmacy paid its wholesaler, by updating their maximum allowable cost lists (the price lists PBMs pay pharmacies from) and letting pharmacies appeal low rates. The PBMs' trade group argued that ERISA, the federal law on employer benefit plans, overrode it. On 10 December 2020 the US Supreme Court ruled 8–0, with Justice Barrett taking no part, that the act is "merely a form of cost regulation" and is not pre-empted.

    supremecourt.gov

    Credit

    the Arkansas attorney general's office; opinion by Justice Sonia Sotomayor

  7. 2024

    A PBM drops Humira

    On 1 April 2024 CVS Caremark removed AbbVie's Humira, the leading anti-inflammatory drug, from its major national commercial formularies and preferred biosimilars, close copies of a biologic medicine. The main one was Hyrimoz, made by Sandoz and co-branded with Cordavis, a CVS Health subsidiary. A July 2024 report by Samsung Bioepis, which sells a rival biosimilar, put Humira's US share at 82% and Hyrimoz's at 13%, while nine other biosimilars, some priced about 85% below Humira, held under 5% between them. CVS says 97% of adalimumab prescriptions on its formularies were filled with a preferred biosimilar within weeks.

    Lessona place on the formulary moved the market more than a lower price did.

    biospace.combusiness.caremark.com

    Credit

    CVS Caremark, Sandoz and Cordavis

Watch for

  1. Insulin rebate cases settled

    The FTC's case against the three largest PBMs alleged that they pushed insulin makers to compete on the size of rebates off inflated list prices rather than on net price, raising what patients paid. Its settlement with Express Scripts, announced on 4 February 2026, requires it, among other terms, to stop preferring high-list-price versions of a drug over identical low-list-price versions on its standard formularies, to offer plans a standard design in which members' cost-sharing is based on net cost, and to pay community pharmacies their acquisition cost plus a fee. A similar settlement with CVS Caremark followed on 14 July 2026; the case against Optum Rx was withdrawn from adjudication to consider a proposed consent agreement. The FTC projects up to $7 billion and up to $8.5 billion in patient savings over ten years from the two settlements.

    Achieved whenthe orders are final and an outside audit, or the reports the orders require, shows net-cost cost-sharing in use and savings near the FTC's projections.

    ftc.govftc.gov

    Claimed by

    the FTC, February and July 2026

  2. A rebate-free model

    Cigna said on 27 October 2025 that its PBM, Express Scripts, would move to a rebate-free model: discounts shown at the pharmacy counter, the lowest of several prices charged, and pharmacies paid their cost plus a dispensing fee. Cigna's fully insured plans are to adopt it in 2027 and all Express Scripts clients are to get it as the standard offering from 2028. Cigna's Evernorth unit estimates that members will save an average of 30% a month on brand-name drugs.

    Achieved whenCigna's insured plans run on the model in 2027 and an outside party, such as an auditor or a plan sponsor publishing its own figures, measures what members paid against the rebate model.

    fiercehealthcare.com

    Claimed by

    Cigna's Evernorth, October 2025

Open

  1. 01

    Part D costs, recomputed openly

    Open-source software that takes an invented list of drugs and doses and works out, for every Medicare drug plan in a county, what the enrollee would pay over the year under the current benefit rules (deductible, coverage phases and the $2,100 cap), using only CMS's public monthly formulary, pharmacy network and cost files. Then compare its answers with Medicare Plan Finder, the government's own tool, for hundreds of invented drug lists, and explain every difference.

    The brief
    Credit · unclaimed
  2. 02

    High-price twins, counted monthly

    A public monthly count of how plans treat drugs sold in two identical versions at different list prices, such as Humira and its unbranded version, or a brand-name insulin and its unbranded twin. For each pair and each Medicare drug plan, record from CMS's formulary file whether each version is covered, on which tier, and whether it needs prior authorization or step therapy; add the standard commercial formularies the three largest PBMs publish. The FTC's 2026 settlements bar Express Scripts and CVS Caremark from preferring the high-list-price version of an identical drug on their standard formularies, so the count also shows whether that stops.

    The brief
    Credit · unclaimed

Open 01 · the brief

Part D costs, recomputed openly

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

Open-source software that takes an invented list of drugs and doses and works out, for every Medicare drug plan in a county, what the enrollee would pay over the year under the current benefit rules (deductible, coverage phases and the $2,100 cap), using only CMS's public monthly formulary, pharmacy network and cost files. Then compare its answers with Medicare Plan Finder, the government's own tool, for hundreds of invented drug lists, and explain every difference.

Why it is still open

CMS publishes the files but warns that Plan Finder's pricing is refreshed every two weeks, so the files "may not match exactly" what the tool shows. CMS's own out-of-pocket cost (OOPC) model estimates costs for an average beneficiary, not for a given list of drugs. A November 2026 search found loaders for the files, such as the CodeRx project's SageRx, but no open project that reproduces Plan Finder's estimates.

data.cms.govcms.govcoderxio.substack.com

Built with what exists

CMS's monthly Part D public use files (plan, formulary, pharmacy network, beneficiary cost and insulin cost files); SageRx to load them; Python and SQL; a web agent such as Browser Use to enter the invented drug lists into Plan Finder and save its answers at a low request rate (see the Note "Deleting 80% to start over").

  1. First step

    Load one month's files and reproduce Plan Finder's yearly cost for one invented list of three generic drugs in one county.

  2. Done looks like

    for 500 invented drug lists in 20 counties, the open tool's yearly cost is within 2% of Plan Finder's for at least 95% of plan-and-list pairs, with each larger gap explained, and the code, test lists and results published.

Open 02 · the brief

High-price twins, counted monthly

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A public monthly count of how plans treat drugs sold in two identical versions at different list prices, such as Humira and its unbranded version, or a brand-name insulin and its unbranded twin. For each pair and each Medicare drug plan, record from CMS's formulary file whether each version is covered, on which tier, and whether it needs prior authorization or step therapy; add the standard commercial formularies the three largest PBMs publish. The FTC's 2026 settlements bar Express Scripts and CVS Caremark from preferring the high-list-price version of an identical drug on their standard formularies, so the count also shows whether that stops.

Why it is still open

Studies have measured one drug at a time, once. A June 2024 research letter in JAMA found that in January 2024 nearly all Part D plans covered Humira, about half covered an adalimumab biosimilar, and only 1.5% of the plans covering both put the biosimilar on a lower tier. No standing count across all such pairs and both markets was found in November 2026; the FTC's terms are in its settlement release.

mdedge.comftc.gov

Built with what exists

CMS's monthly Basic Drugs Formulary File, which gives each plan's drug codes, tiers and prior authorization, step therapy and quantity limit flags; the FDA's Purple Book of licensed biologics and its National Drug Code Directory to pair identical products; pdfplumber and a low-cost AI model to read the PBMs' formulary PDFs into tables (see the Note "The jobs agents repeat"); Python.

data.cms.gov

  1. First step

    Take the adalimumab and insulin glargine pairs and work out their tiers in every Part D plan from this month's formulary file.

  2. Done looks like

    at least 30 pairs tracked every month for a year across all Part D plans and the three national commercial formularies, with the share of plans preferring the high-price version for each pair, 200 random rows checked by two people, and the data and code published.